Gene Therapy Breakthrough: Saponins Show Potential as Adjuvants in mRNA Vaccines

Strategic Insights -

A team of researchers from Oregon State University has made a significant discovery in the field of gene therapy. By incorporating 40 saponins into a model lipid nanoparticle (LNP) formulation, they found that certain saponins, such as quillaic acid and macranthoidin B, can increase the LNP transfection efficiency and endosomal disruption. The researchers discovered that these saponins can activate the innate immune system, measured by the cell-based assays of interferon regulatory factor (IRF) and NF-kB pathway activation. The study suggests that saponins may serve as adjuvants in mRNA vaccines, potentially decreasing the risk of vaccine-associated adverse events.

Key Takeaways:

  • The research team incorporated 40 saponins into a model LNP formulation and evaluated their performance in vitro and in vivo.
  • Two saponins, quillaic acid and macranthoidin B, were found to increase the LNP transfection efficiency and endosomal disruption.
  • Saponin formulations demonstrated cargo-dependent activation of the innate immune system, measured by the cell-based assays of IRF and NF-kB pathway activation.
  • Quillaic acid LNPs resulted in higher titers of anti-OVA IgG2a in the vaccination studies compared to a 'naive' LNP control, suggesting a more Th1-biased immunopathology.
  • The study suggests that saponins may serve as adjuvants in mRNA vaccines, potentially decreasing the risk of vaccine-associated adverse events.
  • The research has significant implications for the development of new mRNA vaccines and the improvement of existing ones.
  • The study was funded by Oregon State University, National Institutes of Health, National Heart, Lung, And Blood Institute, Lam Therapeutics, Oregon Health And Science University, and National Cancer Institute.
  • The research team, led by Antony Jozic, includes researchers from Oregon State University, Portland, Oregon, United States.

Statistics:

  • 40 saponins were incorporated into the model LNP formulation.
  • 2 saponins, quillaic acid and macranthoidin B, were found to increase the LNP transfection efficiency and endosomal disruption.
  • The vaccination studies showed higher titers of anti-OVA IgG2a in quillaic acid LNPs compared to a 'naive' LNP control (data not specified).
  • The research has significant implications for the development of new mRNA vaccines and the improvement of existing ones.

Sources:

  • "Exploring the potential of saponins as adjuvants in lipid-nanoparticle-based mRNA vaccines." Molecular Therapy: Methods & Clinical Development, 2025, 33(2): 101495.
  • Oregon State University. Department of Pharmaceutical Sciences, College of Pharmacy, Portland OR 97201, United States.